IGHE
Immunoglobulin heavy constant epsilon
As of the edition of 20 October 2026, IGHE (immunoglobulin heavy constant epsilon, UniProt P01854) has 5 drugs tested at it and 5 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01854
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 39
- Disease areas
- Immune system; Lungs and airways; Skin and connective tissue; Ear, nose and throat; Inherited and neonatal; Infections; Blood and lymph; Digestive system
- Registered trials of its drugs
- 180
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Omalizumab | Marketed | Phase 4 | Ended 2015 |
| Ligelizumab | Stopped | Phase 3 | none listed |
| CMAB007 | Active | Phase 3 | none listed |
| Quilizumab | Went quiet | Phase 2 | none listed |
| MEDI-4212 | Went quiet | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 3 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Novartis | Route B |
| AstraZeneca | Route A |
The other 3 companies at IGHE
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at IGHE, ranked, with the facts behind eachRequest access. Nothing is shown until you do.